Ursolic acid nanoparticles for glioblastoma therapy

Nanomedicine. 2023 Jun:50:102684. doi: 10.1016/j.nano.2023.102684. Epub 2023 Apr 25.

Abstract

Background: Glioblastoma multiforme (GBM) is the most common and fatal primary tumor in the central nervous system (CNS). The effect of chemotherapy of GBM is limited due to the existence of blood-brain barrier (BBB). The aim of this study is to develop self-assembled nanoparticles (NPs) of ursolic acid (UA) for GBM treatment.

Methods: UA NPs were synthesized by solvent volatilization method. Western blot analysis fluorescent staining and flow cytometry were launched to explore the anti-glioblastoma mechanism of UA NPs. The antitumor effects of UA NPs were further confirmed in vivo using intracranial xenograft models.

Results: UA were successfully prepared. In vitro, UA NPs could significantly increase the protein levels of cleaved-caspase 3 and LC3-II to strongly eliminate glioblastoma cells through autophagy and apoptosis. In the intracranial xenograft models, UA NPs could further effectively enter the BBB, and greatly improve the survival time of the mice.

Conclusions: We successfully synthesized UA NPs which could effectively enter the BBB and show strong anti-tumor effect which may have great potential in the treatment of human glioblastoma.

Keywords: Autophagy; Glioblastoma; Nanoparticles; Ursolic acid.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis
  • Brain Neoplasms* / drug therapy
  • Brain Neoplasms* / metabolism
  • Cell Line, Tumor
  • Glioblastoma* / metabolism
  • Humans
  • Mice
  • Nanoparticles*
  • Ursolic Acid